Elicio Therapeutics, Inc. (NASDAQ:ELTX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Elicio Therapeutics, Inc. (NASDAQ:ELTX) have been given an average recommendation of “Moderate Buy” by the six analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $19.75.

A number of research analysts recently issued reports on the stock. LADENBURG THALM/SH SH started coverage on shares of Elicio Therapeutics in a research note on Thursday, June 18th. They issued a “buy” rating and a $12.00 target price on the stock. JonesTrading downgraded Elicio Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Weiss Ratings raised Elicio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 14th. HC Wainwright upped their price target on Elicio Therapeutics from $17.00 to $23.00 and gave the stock a “buy” rating in a report on Monday, June 15th. Finally, Wall Street Zen cut Elicio Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th.

Elicio Therapeutics Stock Down 0.2%

Shares of NASDAQ:ELTX traded down $0.01 on Thursday, reaching $2.88. The company had a trading volume of 54,013 shares, compared to its average volume of 800,847. Elicio Therapeutics has a twelve month low of $2.66 and a twelve month high of $16.00. The stock has a 50-day moving average price of $6.44 and a 200 day moving average price of $8.85. The stock has a market capitalization of $55.07 million, a P/E ratio of -1.21 and a beta of 1.26. The company has a quick ratio of 2.24, a current ratio of 2.24 and a debt-to-equity ratio of 5.75.

Elicio Therapeutics (NASDAQ:ELTX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.16). On average, equities analysts expect that Elicio Therapeutics will post -2.08 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Susquehanna International Group LLP increased its stake in Elicio Therapeutics by 606.1% during the third quarter. Susquehanna International Group LLP now owns 120,207 shares of the company’s stock valued at $1,315,000 after acquiring an additional 103,184 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Elicio Therapeutics by 332.7% during the 1st quarter. Renaissance Technologies LLC now owns 121,631 shares of the company’s stock worth $1,300,000 after purchasing an additional 93,520 shares in the last quarter. 683 Capital Management LLC acquired a new stake in shares of Elicio Therapeutics during the 4th quarter worth approximately $449,000. Geode Capital Management LLC increased its position in shares of Elicio Therapeutics by 56.0% during the second quarter. Geode Capital Management LLC now owns 120,831 shares of the company’s stock valued at $933,000 after purchasing an additional 43,364 shares during the period. Finally, Royal Bank of Canada acquired a new position in shares of Elicio Therapeutics in the first quarter valued at $225,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.